Zhendong Deng
Overview
Explore the profile of Zhendong Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
232
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deng Z, Sun S, Zhou N, Peng Y, Cheng L, Yu X, et al.
Adv Sci (Weinh)
. 2024 Dec;
12(5):e2407681.
PMID: 39656865
Multiple myeloma (MM) is a cancer of plasma cells caused by abnormal gene expression and interactions within the bone marrow (BM) niche. The BM environment significantly influences the progression of...
2.
Wei R, Cao Y, Wu H, Liu X, Jiang M, Luo X, et al.
Aging (Albany NY)
. 2023 Aug;
15(16):8220-8236.
PMID: 37606987
Multiple myeloma (MM) is the second most common hematological malignancy, in which the dysfunction of the ubiquitin-proteasome pathway is associated with the pathogenesis. The valosin containing protein (VCP)/p97, a member...
3.
Li R, Ke M, Qi M, Han Z, Cao Y, Deng Z, et al.
Exp Hematol Oncol
. 2022 Oct;
11(1):77.
PMID: 36271440
Background: Glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme in the pentose phosphate pathway (PPP) is well-established as an aberrantly expressed protein in numerous clinical diseases; however, its role in cancer,...
4.
Zhang Y, Deng Z, Sun S, Xie S, Jiang M, Chen B, et al.
Front Oncol
. 2022 Aug;
12:967811.
PMID: 35978804
Multiple myeloma (MM) is a clinically distinctive plasma cell malignancy in the bone marrow (BM), in which epigenetic abnormalities are featured prominently. Epigenetic modifications including acetylation have been deemed to...
5.
Tang X, Deng Z, Ding P, Qiang W, Lu Y, Gao S, et al.
J Exp Clin Cancer Res
. 2022 Mar;
41(1):85.
PMID: 35260179
Backgroud: Multiple myeloma (MM) is an incurable plasma cell malignancy in the bone marrow (BM), while immunoglobulin D type of MM (IgD MM) is a very rare but most severe...
6.
Tang X, Guo M, Ding P, Deng Z, Ke M, Yuan Y, et al.
Signal Transduct Target Ther
. 2021 Oct;
6(1):361.
PMID: 34620840
Multiple myeloma (MM) is an incurable plasma cell malignancy in the bone marrow characterized by chromosome instability (CIN), which contributes to the acquisition of heterogeneity, along with MM progression, drug...
7.
Chen X, Huang L, Yang T, Xu J, Zhang C, Deng Z, et al.
Front Oncol
. 2021 Jun;
11:667451.
PMID: 34094960
Recent studies have identified pleiotropic roles of methyltransferase-like 3 (METTL3) in tumor progression. However, the roles of METTL3 in esophageal squamous cell carcinoma (ESCC) are still unclear. Here, we investigated...
8.
Lin H, Chen X, Zhang C, Yang T, Deng Z, Song Y, et al.
Biomed Pharmacother
. 2021 Jan;
136:111202.
PMID: 33453607
Purpose: EF24, a synthetic analogue of curcumin, was developed as an anti-tumor compound to induce apoptosis, inhibit proliferation and metastasis in various cancers. However, whether EF24 induces ferroptosis in osteosarcoma...
9.
Ou L, Lin H, Song Y, Tan G, Gui X, Li J, et al.
Int J Nanomedicine
. 2020 Aug;
15:5131-5146.
PMID: 32764941
Background: Gene therapy is considered a novel way to treat osteosarcoma, and microRNAs are potential therapeutic targets for osteosarcoma. miR-214 has been found to promote osteosarcoma aggression and metastasis. Graphene...
10.
Ou L, He X, Liu N, Song Y, Li J, Gao L, et al.
Mol Med Rep
. 2020 Feb;
21(3):1449-1460.
PMID: 32016470
Fibroblast growth factor receptors (FGFRs) have been implicated in the malignant transformation and chemoresistance of epithelial ovarian cancer; however, the underlying molecular mechanisms are poorly understood. Increased sialyltransferase activity that...